ExpreS2ion: Phase I update on ES2B-C001 builds momentum ahead of end-2026 readout
19 maj, 15:25
19 maj, 15:25
ExpreS2ion today announced an update to the Phase I program for ES2B-C001 alongside additional preliminary observations and study design changes. Anti-HER2 antibody responses have now been observed in 9 of 9 evaluable patients, up from 8 of 9 in March, with titres maintained at later follow-up.
19 maj, 15:25
ExpreS2ion today announced an update to the Phase I program for ES2B-C001 alongside additional preliminary observations and study design changes. Anti-HER2 antibody responses have now been observed in 9 of 9 evaluable patients, up from 8 of 9 in March, with titres maintained at later follow-up.
Aktieråd
Aktieråd
1 DAG %
Senast
OMX Stockholm 30
0,97%
(vid stängning)
Nato
Idag, 15:35
Sverige tecknar teknikavtal med USA
Boozt
Idag, 14:30
Boozt: Med högre förväntningar
OMX Stockholm 30
1 DAG %
Senast
3 146,13